Syndax Pharmaceuticals (SNDX) Net Cash Flow (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Net Cash Flow of -$4.0 million for Q1 2026, down 4385.56% year-over-year from $94200.2 in Q1 2025, and down 122.42% quarter-over-quarter from $18.0 million in Q4 2025.
Syndax Pharmaceuticals (SNDX) Net Cash Flow (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Net Cash Flow history runs 12 years deep, the most recent figure standing at -$4.0 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 4385.56% year-over-year to -$4.0 million; the TTM figure through Mar 2026 stood at -$23.2 million (down 158.95% YoY), while the FY2025 annual figure was -$19.3 million, up 86.36% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$4.0 million, down from $18.0 million in the prior quarter.
- The five-year high for Net Cash Flow was $200.8 million in Q4 2023, with the low at -$180.8 million in Q1 2024.
- The 5-year median for Net Cash Flow is -$2.7 million (2023), against an average of -$5.4 million.
- The sharpest annual moves came in 2023 and 2026: Net Cash Flow jumped 6641.99% in 2023, then tumbled 4385.56% in 2026.
- Syndax Pharmaceuticals' Net Cash Flow stood at $3.0 million in 2022, then surged by 6641.99% to $200.8 million in 2023, then tumbled by 89.51% to $21.1 million in 2024, then declined by 14.51% to $18.0 million in 2025, then tumbled by 122.42% to -$4.0 million in 2026.
- Business Quant data shows SNDX's Net Cash Flow at -$4.0 million in Q1 2026, $18.0 million in Q4 2025, and $8.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn | 205.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 205.58 Mn |
| Jun 30, 2026 | 205.58 Mn |
| Mar 31, 2026 | -4.04 Mn |
| Mar 31, 2026 | -4.04 Mn |
| Dec 31, 2025 | 18.01 Mn |
| Dec 31, 2025 | 18.01 Mn |
| Sep 30, 2025 | 8.17 Mn |
| Sep 30, 2025 | 8.17 Mn |
| Jun 30, 2025 | -45.36 Mn |
| Jun 30, 2025 | -45.36 Mn |
| Mar 31, 2025 | -90,000.00 |
| Mar 31, 2025 | -90,000.00 |
| Dec 31, 2024 | 21.06 Mn |
| Dec 31, 2024 | 21.06 Mn |
| Sep 30, 2024 | 27.62 Mn |
| Sep 30, 2024 | 27.62 Mn |
| Jun 30, 2024 | -9.22 Mn |
| Jun 30, 2024 | -9.22 Mn |
| Mar 31, 2024 | -180.78 Mn |
| Mar 31, 2024 | -180.78 Mn |